Chenguang Biotech Group (300138) — Capital Reinvestment Ratio
Latest as of September 2025:
0.07x
Chenguang Biotech Group (300138) has a Capital Reinvestment Ratio of 0.07x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥524.96 Million) in capital expenditures (CN¥37.63 Million). See Chenguang Biotech Group free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.07x
Capex / Operating Cash Flow
Operating Cash Flow
CN¥524.96 Million
CNY
Capital Expenditures
CN¥37.63 Million
CNY
Data as of
Sep 2025
Most recent filing
Chenguang Biotech Group Capital Reinvestment Ratio (2008–2022)
This chart tracks Chenguang Biotech Group's Capital Reinvestment Ratio across 7 annual periods.
Annual Capital Reinvestment Ratio for Chenguang Biotech Group (2008–2022)
Year-by-year Capital Reinvestment Ratio for Chenguang Biotech Group from 2008 to 2022. For live market cap and broader valuation context, see 300138 market cap overview.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.24x | CN¥734.81 Million | CN¥176.03 Million | ▼ -94.5% |
| 2021 | 4.39x | CN¥63.90 Million | CN¥280.82 Million | ▲ +432.5% |
| 2020 | 0.83x | CN¥529.41 Million | CN¥436.88 Million | ▲ +515.0% |
| 2014 | 0.13x | CN¥272.96 Million | CN¥36.62 Million | ▼ -93.9% |
| 2011 | 2.21x | CN¥82.18 Million | CN¥181.72 Million | ▼ -10.0% |
| 2009 | 2.46x | CN¥27.23 Million | CN¥66.90 Million | ▼ -14.5% |
| 2008 | 2.87x | CN¥9.06 Million | CN¥26.05 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow